Neurotoxicity Prophylaxis With Intrathecal Dexamethasone and Simvastatin Post Axi-Cel
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Open-label, single-arm, single center pilot study to assess safety and feasibility of
administering dexamethasone intrathecally and simvastatin orally during axicabtagene
ciloleucel (axi-cel) treatment. Feasibility will be measured by the proportion of patients
completing two-thirds (2/3) of their assigned treatments. The study will be deemed feasible
if 2/3 or more of the patients complete 2/3 or more of their allocated treatments.